期刊文献+

成纤维细胞生长因子21对大鼠血管平滑肌钙化的影响及机制 被引量:7

Effects and mechanism of fibroblast growth factor 21 on rat vascular smooth muscle cells calcification
原文传递
导出
摘要 目的 通过建立离体血管平滑肌细胞钙化模型,观察成纤维细胞生长因子21 (FGF21)对血管钙化的影响,并探讨其机制.方法 使用氯化钙和β磷酸甘油诱导离体大鼠主动脉血管平滑肌细胞钙化.将细胞分为对照组(使用常规培养基)、钙化组(使用钙化培养基)、FGF21组(使用钙化培养基和FGF21)、PD166866组[使用钙化培养基、FGF21和成纤维细胞生长因子受体1(FGFR1)抑制剂PD166866]和GW9962组(使用钙化培养基、FGF21和过氧化物酶体增殖因子受体γ抑制剂GW9662).通过细胞内钙含量、碱性磷酸酶活性和茜素红染色检测血管平滑肌细胞钙化情况.FGFR1、β-Klotho、骨钙素和平滑肌22α的蛋白含量和mRNA表达水平分别用Western blot和Real-timePCR检测.结果 (1)与对照组比较,钙化组的FGFR1和β-Klotho蛋白水平(P<0.05)和mRNA水平(P<0.01)均较低.(2)与钙化组比较,FGF21组钙含量、碱性磷酸酶活性和骨钙素的表达量较少(P <0.05或0.01),同时平滑肌22α的蛋白和mRNA水平较高(P均<0.05).茜素红染色显示,与钙化组比较,FGF21组的红色钙化结节较少.(3)PD166866组与钙化组之间的钙含量、碱性磷酸酶活性和茜素红染色结果差异均无统计学意义(P均>0.05).(4) GW9662组与钙化组之间的钙含量、碱性磷酸酶活性和茜素红染色结果差异均无统计学意义(P均>0.05).结论 在大鼠血管平滑肌钙化模型中,FGFR1和β-Klotho的蛋白及mRNA水平下调,降低了FGF21抑制血管平滑肌细胞钙化的作用;FGF21通过过氧化物酶体增殖因子受体γ通路减轻血管钙化. Objective To observe the effect and mechanism of fibroblast growth factor 21 (FGF21) on rat vascular smooth muscle cells (VSMCs) calcification in vitro.Methods VSMCs was treated with calcification medium containing calcium chloride and β-glycerophosphate to induce rat VSMCs calcification in vitro.VSMCs were divided into 5 groups: the control group (cultured in normal medium), the calcification group (incubated in calcified medium), the FGF21 group (cultured in calcified medium and FGF21), the PD166866 group (cultured in calcified medium and FGF21 and PD166866, inhibitor of fibroblast growth factor receptor-1 (FGFR1)), the GW9662 group (cultured in calcified medium and FGF21 and GW9662, inhibitor of peroxisome proliferators activated receptor-γ (PPAR-γ)).The calcification of VSMCs was detected by calcium content, alkaline phosphatase activity and alizarin red staining.The protein and mRNA expression of FGFR1, β-Klotho, osteocalcin and smooth muscle 22α (SM22α) were determined by western blot analysis and realtime-PCR, respectively.Results (1) The mRNA (P 〈 0.01) and protein expressions of β-Klotho and FGFR1 were significantly downregulated in calcification group compared with control group (P 〈 0.05 or 0.01).(2)The protein levels and mRNA expression of calcium content, alkaline phosphatase activity and osteocalcin were significantly downregulated, while the protein levels and mRNA of SM22α were significantly increased in FGF21 group compared with calcification group (all P 〈 0.05).Moreover, alizarin red staining verified positive red nodules on calcified VSMCs was significantly reduced in FGF21 group than in calcification group.(3)Calcium content, alkaline phosphatase activity and alizarin red staining were similar between PD166866 group and calcification group (all P 〉 0.05).(4) Calcium content, alkaline phosphatase activity and alizarin red staining were similar between GW9662 group and calcification group (all P 〉 0.05).Conclusion The inhibition of VSMCs calcification by FGF21 is mediated by further downregulating FGFR1 and β-Klotho while activating PPAR-γpathways.
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2015年第10期879-886,共8页 Chinese Journal of Cardiology
基金 国家自然科学基金(81070227) 北京市教育委员会科技计划面上项目(km201110025019) 北京市自然科学基金项目(7142048)
关键词 成纤维细胞生长因子 钙质沉着症 PPARΓ Fibroblast growth factors Calcinosis PPAR gamma
  • 相关文献

参考文献2

二级参考文献20

  • 1Nishimura T, Nakatake Y, Konishi M,et al. Identification of a novel FGF, FGF21, preferentially expressed in the liver. Biochim Biophys Aeta,2000,1492:203-206.
  • 2Izumiya Y, Bina HA, Ouchi N, et al. FGF21 is an Akt- regulated myokine. FEBS Letters, 2008,582:3805-3810.
  • 3Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology, 2008, 149: 6018-6027.
  • 4Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes, 2009,58:250-259.
  • 5Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology, 2007,148 : 774-781.
  • 6Lundasen T, Hunt MC, Nilsson LM, et al. PPAR alpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun, 2007,360:437-440.
  • 7Galman C, Lundason T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPAR alpha activation in man. Cell metab,2008, 8 : 169-174.
  • 8Nishida M, Carley WW, Gerritsen ME, et al. Isolation and characterization of human and rat cardiac microvascular endothelial cells. Am J Physiol, 1993,264: 639-652.
  • 9Weisensee D, Seeger T, Bittner A, et al. Cocultures of fetal and adult cardiomyocytes yield rhythmically beating rod-shaped heart cells from adult rats. In Vitro, 1995,31: 190-195.
  • 10Mate Kiss,Zsolt Czimmerer,Laszlo Nagy.The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function - from physiology to pathology[J].The Journal of Allergy and Clinical Immunology.2013

共引文献37

同被引文献59

  • 1王中群,李丽华,严金川,徐绥宁.糖基化终末产物与动脉粥样硬化的关系[J].中国动脉硬化杂志,2015,23(1):94-100. 被引量:16
  • 2王柏川,叶剑.地塞米松对大鼠晶状体上皮细胞成纤维细胞生长因子受体表达的影响[J].眼科新进展,2007,27(10):750-753. 被引量:3
  • 3Nunes M,Li Y,Sun C,et al.Fibroblast growth factors as tissue repair and regeneration therapeutics.Peer J,2016,4:e1535.
  • 4Guan D,Zhao L,Chen D,et al.Regulation of fibroblast growth factor 15/19 and 21 on metabolism:in the fed or fasted state.J Transl Med,2016,14:63.
  • 5Nies V,Sancar G,Liu W,et al.Fibroblast growth factor signaling in metabolic regulation.Front Endocrinol(Lausanne),2015,6:193.
  • 6Nishimura T,Nakatake Y,Konishi M,et al.Identification of a novel FGF,FGF-21,preferentially expressed in the liver.Biochim Biophys Acta,2000,1492:203-206.
  • 7Gao M,Ma Y,Cui R,et al.Hydrodynamic delivery of FGF21gene alleviates obesity and fatty liver in mice fed a high-fat diet.J Control Release,2014,185:1-11.
  • 8Novotny D,Vaverkova H,Karasek D,et al.Evaluation of total adiponectin,adipocyte fatty acid binding protein and fibroblast growth factor 21 levels in individuals with metabolic syndrome.Physiol Res,2014,63:219-228.
  • 9Jin L,Lin Z,Xu A.Fibroblast growth factor 21 protects against atherosclerosis via fine-tuning the multiorgan crosstalk.Diabetes Metab J,2016,40:22-31.
  • 10Salgado V,Salgado J.Fibroblast growth factor-21:a metabolic regulator or something more..Clin Endocrinol(Oxf),2014,81:938-940.

引证文献7

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部